FIELD: pharmaceutics.
SUBSTANCE: compounds of formula I' or their pharmaceutically acceptable salts, pharmaceutical compositions based on them, as well as a method for treating cancer, a method for inducing ER stress, a method for inducing an unfolded protein response (UPR), a method for inducing an unfolded protein response (UPR) and a method for inducing releasing calcium from the endoplasmic reticulum (ER) through a putative Ca2+ channel known as Wolframin (WFS1) using them. In the general formula I', ring A is a ring selected from phenyl, an 8-12 membered partially unsaturated bicyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, a 5-6 membered heteroaromatic ring containing 1 -4 heteroatoms independently selected from nitrogen or sulfur; or an 8-10 membered bicyclic heteroaromatic ring containing 1-5 heteroatoms independently selected from nitrogen; each R1 independently represents hydrogen or straight or branched hydrocarbon chain C1-3, optionally substituted with 1-6 halogens; each of R2 independently represent hydrogen, halogen, -CN, -NO2, -C(O)OR, -C(O)NR2, -NR2, -NRC(O)R, -NRC(O)OR , -NRS(O)2R, -OR, -P(O)R2, -SR, -S(O)R, -S(O)2R, -S(O)(NH)R, -S(O)2NR2 or R; the two R2 groups are optionally taken together to obtain =O; or two R 2 groups are optionally taken together with their intermediate atoms, obtaining a 3-membered saturated spirocyclic ring containing 0 of the heteroatom; each R3 independently represents hydrogen, -OH or a linear or branched hydrocarbon chain C1-3; or the two R3 groups are optionally taken together to give =O; or the two R3 groups are optionally taken together to give =CH2 ; or the two R3 groups are optionally taken together with their intermediate atoms, yielding a 3-8 membered saturated spirocyclic ring containing 0-2 of the heteroatoms independently selected from oxygen; X represents -O- or -CH2-; m is 0, 1 or 2; n is 0, 1, 2, 3, 4 or 5; and p is 0, 1 or 2.
EFFECT: anti-proliferative compounds are proposed.
67 cl, 6 tbl, 60 ex
I’
Title | Year | Author | Number |
---|---|---|---|
PROTEIN KINASE INHIBITORS FOR ENHANCING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2019 |
|
RU2822216C2 |
BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
GLYCOLATOXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES | 2018 |
|
RU2805308C2 |
SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2014 |
|
RU2667520C9 |
JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
COMPOUNDS WHICH ARE ANTAGONISTS OF THE A3-ADENOSINE RECEPTOR, A METHOD FOR PREPARING THEM AND MEDICAL USE THEREOF | 2017 |
|
RU2737157C2 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2661896C2 |
[1,8]NAPHTHYRIDINE DERIVATIVES, USEFUL AS INHIBITORS OF HCV VIRUS REPLICATION | 2006 |
|
RU2467007C2 |
Authors
Dates
2024-01-19—Published
2019-04-23—Filed